StreetInsider.com News Articles

Form S-1 AIAI Holdings Corp

Mon, 19 Oct 2026 17:25:00 -0400

http://archive.fast-edgar.com/20261019/AQ24R22CZZ2RATOZ2A9H2ZY2MNFCZZ22Z282

Filed on: October 19, 2026

AIAI Holdings to Present at the 20th Annual LD Micro Main Event

Wed, 14 Oct 2026 08:50:00 -0400

DALLAS, TX / ACCESS Newswire / October 14, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced that Chief Executive Officer Todd Furniss will present at the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

AIAI Holdings is scheduled to present on Wednesday, October 21, 2026 at 02:30 PM PT. Additionally, Mr. Furniss will be available for 1x1's. Please register and request meetings through LD

AIAI Holdings to Present at the 20th Annual LD Micro Main Event

Wed, 14 Oct 2026 08:50:00 -0400

AIAI Holdings is scheduled to present on Wednesday, October 21, 2026 at 02:30 PM PT. Additionally, Mr. Furniss will be available for 1x1's. Please register and request meetings through LD

Rochon family buys $26.8M in AIAI Holdings shares

Thu, 08 Oct 2026 16:09:20 -0400

Entities controlled by the family of John P. Rochon have acquired approximately $26.8 million in shares of AIAI Holdings Corporation (NASDAQ: AIAI) through privately negotiated transactions with an existing large stockholder, according to a company press release.

The purchases increase the Rochon family's existing ownership stake in the Dallas-based company, which describes itself as an AI-enabled diversified holding company.

CEO Todd Furniss commented on the transactions: "We are grateful for the continued confidence that the Rochons have in the Company's operating strategy and vision for long-term value creation as evidenced by these additional acquisitions of a substantial number of shares of the

Rochon family buys $26.8M in AIAI Holdings shares

Thu, 08 Oct 2026 16:09:20 -0400

The purchases increase the Rochon family's existing ownership stake in the Dallas-based company, which describes itself as an AI-enabled diversified holding company.

Rochon Family Executes Additional Strategic Purchase of $26.8 Million of AIAI Holdings Shares

Thu, 08 Oct 2026 16:05:00 -0400

DALLAS, TX / ACCESS Newswire / October 8, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced that certain entities controlled by the family of John P. Rochon have acquired approximately $26.8 million of Ai² shares through privately negotiated transactions with an existing large stockholder.

These transactions represent meaningful incremental investments by the Rochon family further increasing their already substantial ownership positions in Ai². The purchases underscore their deep and continuing conviction in the Company's long-term strategy, its

Rochon Family Executes Additional Strategic Purchase of $26.8 Million of AIAI Holdings Shares

Thu, 08 Oct 2026 16:05:00 -0400

NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright’s AI-Based Drug Discovery and Development Conference

Wed, 07 Oct 2026 08:38:00 -0400

Panel discussion to explore competitive differentiation as AI reshapes drug discovery and development

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Dr. Joseph Geraci, Founder and Chief Scientific and Technical Officer, will participate in the H.C. Wainwright 3rd Annual AI Based Drug Discovery and Development Virtual Conference, taking place October 8–9, 2026.

Dr. Geraci will join the panel “Design

NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright’s AI-Based Drug Discovery and Development Conference

Wed, 07 Oct 2026 08:38:00 -0400

Panel discussion to explore competitive differentiation as AI reshapes drug discovery and development

Dr. Geraci will join the panel “Design

NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright’s AI-Based Drug Discovery and Development Conference

Wed, 07 Oct 2026 08:38:00 -0400

Panel discussion to explore competitive differentiation as AI reshapes drug discovery and development

Dr. Geraci will join the panel “Design

NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright’s AI-Based Drug Discovery and Development Conference

Wed, 07 Oct 2026 08:38:00 -0400

Panel discussion to explore competitive differentiation as AI reshapes drug discovery and development

Dr. Geraci will join the panel “Design

Form 4 AIAI Holdings Corp For: Sep 22 Filed by: Affeldt Eric

Wed, 23 Sep 2026 17:49:00 -0400

si-local-file:///var/storage/secattach/20260923/27097534.html

AIAI Holdings signs $200M stock purchase agreement with B. Riley

Mon, 21 Sep 2026 06:07:04 -0400

AIAI Holdings Corporation (NASDAQ: AIAI) entered into a Common Stock Purchase Agreement with B. Riley Principal Capital II, LLC on September 18, 2026, allowing the company to sell up to $200 million in newly issued Class A common stock over a period of up to 36 months.

Under the terms of the agreement, AIAI Holdings retains sole discretion over the timing and amount of any stock sales. Shares will be priced based on the volume weighted average price of the stock during applicable trading periods, less a fixed 3.0% discount. The stock must maintain a closing price above $1.00 per share

AIAI Holdings signs $200M stock purchase agreement with B. Riley

Mon, 21 Sep 2026 06:07:04 -0400

Form 8-K AIAI Holdings Corp For: Sep 18

Mon, 21 Sep 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260921/27082510.html

AIAI Holdings restructures deal to consolidate Messier 42 marketing agreement

Fri, 18 Sep 2026 08:31:00 -0400

AIAI Holdings Corporation (NASDAQ: AIAI) announced that its affiliated entity, Messier 42 LLC, has agreed to contribute a controlling position in the entity holding its military equipment sales marketing agreement to the company, replacing a previously announced letter of intent to acquire a controlling interest in the same entity.

Under the arrangement, 100% of the revenue and EBITDA generated by the Messier 42 entity holding the teaming agreement will be consolidated on AIAI's financial statements. The company will distribute approximately 50% of the resulting free cash flow to Messier 42. No cash or stock consideration is required from AIAI.

AIAI previously stated

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

Fri, 18 Sep 2026 08:30:00 -0400

DALLAS, TX / ACCESS Newswire / September 18, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its affiliated entity, Messier 42 LLC ("M42"), has agreed to contribute to the capital of the Company a controlling position in the entity holding M42's marketing agreement for the sale of military equipment (the "Teaming Agreement").

Under this arrangement, 100% of the revenue and EBITDA generated by the M42 entity which holds the Teaming Agreement will be

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement

Fri, 18 Sep 2026 08:30:00 -0400

Under this arrangement, 100% of the revenue and EBITDA generated by the M42 entity which holds the Teaming Agreement will be

AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare

Thu, 17 Sep 2026 09:25:00 -0400

DALLAS, TX / ACCESS Newswire / September 17, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance announced today that its portfolio company, Constellation Network, through Dôr Technologies, has launched Dôr Patient Journey, a new healthcare intelligence platform. Developed in collaboration with Proactive MD, the platform is actively deployed within Proactive MD's care environment.

Patient Journey represents the first healthcare extension of Dôr's recently launched Retail Intelligence platform, applying the same underlying intelligence architecture, connecting physical-world activity

AIAI Holdings' Constellation Network Launches Dôr Patient Journey with Proactive MD(R), Expanding Transformational AI In Healthcare

Thu, 17 Sep 2026 09:25:00 -0400

AIAI Holdings extends lock-up agreements, pushing share release to 2027

Fri, 11 Sep 2026 08:33:53 -0400

AIAI Holdings Corporation (NASDAQ: AIAI) has amended its existing lock-up agreements with key shareholders, extending restrictions on the sale of shares originally tied to the company's direct listing.

The amended agreements were signed by the company's founder and chairman, other board members, members of management, and a majority of its largest stockholders.

Under the revised schedule, restrictions on 70% of the currently locked shares will remain in place until mid-February 2027, when the restricted portion drops to 50%. Restrictions then decline to 30% in mid-March 2027, with the remaining 30% released entirely by mid-April 2027.

Todd Furniss, Chief Executive Officer and Co-Founder of

AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value

Fri, 11 Sep 2026 08:30:00 -0400

DALLAS, TX / ACCESS Newswire / September 11, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance announced today that it has entered into amendments to its existing lock-up agreements entered into in connection with the Company's direct listing with holders of the Company's outstanding shares of Class A Common Stock. The list of those signing the amendment includes the Company's founder and Chairman, other members of the Company's board of directors, members of management and

AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value

Fri, 11 Sep 2026 08:30:00 -0400

Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models

Thu, 10 Sep 2026 07:00:00 -0400

NetraAI’s biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested
The study showed improved performance across conventional machine learning, neural-network and foundation-model (including Fable 5) approaches in schizophrenia, major depressive disorder and pancreatic cancer
Findings support what the company believes is the potential of an unbiased discovery-first approach to uncover clinically relevant structure in complex trial data and inform future patient-stratification and trial-enrichment strategies

TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt:

Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models

Thu, 10 Sep 2026 07:00:00 -0400

NetraAI’s biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested
The study showed improved performance across conventional machine learning, neural-network and foundation-model (including Fable 5) approaches in schizophrenia, major depressive disorder and pancreatic cancer
Findings support what the company believes is the potential of an unbiased discovery-first approach to uncover clinically relevant structure in complex trial data and inform future patient-stratification and trial-enrichment strategies

TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: